Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biomarin
Biomarin
BioMarin Rises on Approval of Palynziq (pegvaliase-pqpz)
Fri, 05/25/18 - 08:45 am
Biomarin
Palynziq
PKU
A Big Decision Is Fast-Approaching for This Rare-Disease Drugmaker
Motley Fool
Wed, 05/23/18 - 03:06 pm
Biomarin
pegvaliase
PKU
FDA
Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study
Endpoints
Tue, 05/22/18 - 09:58 am
Biomarin
hemophilia A
valrox
BioMarin Cruises While It Waits on Seventh Approval
Motley Fool
Fri, 04/27/18 - 08:15 pm
Biomarin
pegvaliase
FDA
PKU
earnings
8 Takeout targets to watch in 2018
BioPharma Dive
Sat, 12/16/17 - 08:41 am
M&A
Allergan
Alnylam
Biomarin
Bristol-Myers Squibb
Incyte
Madrigal Pharmaceuticals
Spark Therapeutics
Sucampo
[video]ASH 2017 Recap: These Were the Big Winners and Losers
Motley Fool
Sat, 12/16/17 - 08:39 am
ASH2017
Bluebird Bio
Juno Therapeutics
Spark Therapeutics
Biomarin
JNJ
Celgene
ASH 2017: What you missed
BioPharma Dive
Wed, 12/13/17 - 06:35 pm
ASH17
Biomarin
Spark Therapeutics
Gilead Sciences
Novartis
Juno Therapeutics
AbbVie
Roche
JNJ
5 Biotech Buyout Candidates for 2018
Yahoo/Motley Fool
Wed, 12/13/17 - 09:36 am
biotech
M&A
Biogen
Biomarin
Bluebird Bio
Geron
SAGE Therapeutics
ASH17: Spark gene therapy falls behind BioMarin in hemophilia
BioPharma Dive
Tue, 12/12/17 - 10:50 pm
ASH17
Spark Therapeutics
gene therapy
Biomarin
hemophilia A
SPK-8011
ASH17: BioMarin's gene therapy promises one-time treatment of hemophilia
BioPharma Dive
Sat, 12/9/17 - 02:31 pm
ASH17
Biomarin
gene therapy
hemophilia A
valoctocogene
How much is an FDA shortcut worth to drug developers hustling to an OK? Holding steady at $125M, cash
Endpoints
Mon, 11/27/17 - 11:42 pm
FDA
priority review vouchers
Biomarin
9 Notable Biotechs Presenting At This Year's ASH Meeting
Yahoo
Tue, 11/7/17 - 09:56 am
ASH
Bluebird Bio
LentiGlobin
Ziopharm Oncology
Bellicum
BPX-501
Spark Therapeutics
SPK-8011
Biomarin
BMN 270
Juno Therapeutics
CAR-T
Novartis
Geron
imetelstat
Immunogen
IMGN632
IMGN779
With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy
Endpoints
Sun, 10/29/17 - 10:04 am
Biomarin
gene therapy
BMN 270
hemophilia A
BioMarin says the FDA game clock now ticking on their blockbuster hopeful pegvaliase
Endpoints
Wed, 08/30/17 - 10:01 am
Biomarin
FDA
pegvaliase
PDUFA
Biomarin announces new investments in Ireland
GoInPharma
Sat, 08/12/17 - 11:47 am
Biomarin
Ireland
BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
Endpoints
Tue, 07/18/17 - 09:28 am
Biomarin
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
BioMarin, Spark, raising the stakes for hemophilia
BioPharma Dive
Wed, 07/12/17 - 02:48 pm
Biomarin
Spark Therapeutics
hemophilia
BMN 270
SPK-9001
gene therapy
BioMarin CEO says 'the system will have to determine' the worth of its new $702,000 drug
CNBC
Sun, 04/30/17 - 12:51 pm
Biomarin
Brineura
drug pricing
Batten disease
4 Drug Stocks With Big News Coming in April
Motley Fool
Tue, 04/4/17 - 12:11 am
Neurocrine
Incyte
Eli Lilly
Biomarin
Ingrezza
baricitinib
Brineura
BioMarin Pharmaceutical Inc. Logs a Combined Blockbuster
Motley Fool
Sat, 02/25/17 - 03:19 pm
Biomarin
earnings
Vimizim
Kuvan
Naglazyme
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »